Revolade 75mg tablets | Eltrombopag | MHP

1
Revolade 75mg tablets Eltrombopag MHP

• ELTROMBOPAG 75MG

2
description

• Eltrombopag is sold under the brand name
  Revolade and it is a man-made form of a protein
  that increases production of platelets
  (blood-clotting cells) in your body. Revolade
  75mg can reduces the risk of bleeding by
  increasing platelets in your blood.Revolade
  75mg tablet which is used asprescription drug
  under the guidance of the medical practioners

3
(No Transcript)
4
indication

• Revolade 75mg is an anticancer medication
  which isIndicated for the treatment of patients
  having Severe aplastic Anemia First line
  treatment of severe aplastic Anemia Treatment
  of refractory severe aplastic AnemiaIndicated
  for the treatment to stimulate the growth and
  development of platelets in the bone
  marrowPrimarily indicated for the treatment of
  patients having reduced platelet counts due to
  chronic hepatitis C virus infection

5
(No Transcript)
6
MECHANISM OF ACTION

• Eltrombopag consist of class of drugs
  known as thrombopoietin (TPO) receptor agonists.
  A class of drugs is a group of medications which
  work in a same way.Eltrombopag mechanism by
  raising cells in your bone marrow and causes
  these cells to make more platelets. This effect
  reduces your risk of bleeding.

7
PROPERTIES

• Ingredients  Eltrombopag 
• Strength  75mg
• Package  7 tablets in a strip

8
ADD ME

• AbsorptionHigh plasma concentration is
  2-6 hoursDistributionMaximum human plasma
  protein bounding is gt99 and in blood plasma
  level is 50 to 79Metabolismgenerally
  metabolised via cleavage, oxidation and
  conjugation with glucuronic acid.EliminationRev
  olade 75mg eliminated mainly via feces 59, along
  with 31 via renally excretedRevolade
  75mg tablet Half-life for healthy patients is
  21-23 hours and idiopathic thrombocytopenic
  purpura is 26-35 hours.

9
DOSAGE MANAGEMENT

• The usual dose for Chronic Hepatitis
  C-associated Thrombocytopenia is 25 mg PO qDay.
  Dose is managed in 25 mg accretion q2weeks PRN to
  attain target Plt needed to start/control
  antiviral therapy with pegylated interferon and
  ribavirin not to exceed 100 mg/day 

10
(No Transcript)
11
Severe Aplastic Anemia

• 1.First-line therapy When combination with
  standard immunosuppressive treatment, for
  patients with serious aplastic Anemia (SAA) The
  usual dose for severe Aplastic Anemia 150 mg PO
  qDay for 6 months Avoid taking of more than
  starting dose total duration is 6 months 

12

• 2.Refractory SAA In this condition the drug
  given who fail to respond enough to at least 1
  before immunosuppressive therapy The usual dose
  for Refractory SAA 50 mg PO qDay 
• The recommended dose for Chronic Immune
  Thrombocytopenia is 50 mg PO qDay Adjust dose to
  manage and control platelet count (Plt) gt50 x
  109/L to reduce the risk of bleeding not to
  exceed 75 mg/day

13
PRECAUTIONS

• The drug Revolade 75mg may have high risk
  of severe and probably life-
• threatening hepatotoxicity monitor
  liver function before and during treatment
  While receiving the drug, if patient with hepatic
  impairment (Child-Pugh Class A,
• B, C) initiates therapy for first- line
  treatment of severe aplastic Anemia, reduce
• initial dose

14
PRECAUTIONS

• When treatment, If the patients have
  cataracts, do not use the drug due to
  the Revolade 75mg effects cataracts and make the
  condition worse. Avoid the Revolade 75mg while
  the patients have myelodysplastic syndrome (MDS),
  will increases the risk of death. While on
  treatment with drug Revolade then Portal vein
  thrombosis reported in patients with chronic
  liver disease.

15
(No Transcript)
16
SIDE EFFECTS

• Common side effects of Revolade 75mg 
  Headache Cough Loss of appetite Flu
  Reduced red blood cells Diarrhoea Nausea
  Fever Weakness

17
Serious side effects  

• Swelling of legs Abdomen swelling
  Confusion Chest pain Dyspnea Cloudy
  vision Urine in dark colour Yellowing of your
  skin Sensitivity to light Seeing circles
  around lights

18
(No Transcript)
19

• PREGNANCY
• Pregnancy category is CSafety of drug during
  pregnancy is not established
• LACTATION
• During breast feeding, avoid using of
  drug Revolade 75mg
• STORAGE
• Store at room temperature 20C and 25C.

20
CONTACT US

• EMAIL millionhealthpharmaceuticals_at_gmail.
  com
•  
• PHONE NO 91-9940472902 
• WEBSITE  https//millionpharma.com/eltrombopag-
  75mg.php

21
(No Transcript)